Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Truist Financial analyst Richard Newitter maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of $120.00. The company’s shares closed yesterday at ...

Commanding a market cap of $150.9 billion, Boston Scientific Corporation (BSX) is a global medical device manufacturer that develops, manufactures, and markets a broad range of innovative products.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

Pulsed-field ablation is a new approach to treating a-fib that has already proved very popular in the wake of strong clinical data. Boston Scientific’s Farapulse is the early leader in the field ...

The Boston Zoning Commission voted to approve a new zoning standard requiring new buildings to meet net zero carbon emissions ...

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $110.00. The company’s shares closed ...

Please use one of the following formats to cite this article in your essay, paper or report: APA Boston Scientific. (2025, January 13). Boston Scientific announces agreement to acquire Bolt ...

The Boston Zoning Commission on Wednesday approved the long-debated rules that require newly constructed buildings to reduce energy use and fossil fuel reliance.

The zoning change requires most new buildings to be net zero when they open. The city previously set similar performance ...